Rigby5
Diamond Member
Which is a poor treatment option compared to ~80% reduction shown by Monoclonal Antibody Treatments.
Table: Anti-SARS-CoV-2 Monoclonal Antibodies Clinical Data | COVID-19 Treatment Guidelines
Review clinical data on the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19.www.covid19treatmentguidelines.nih.gov
Sure, but monoclonal antibodies are about 100 times more risky and expensive.